The effect of Pentoxifylline for the treatment of major depression in cardiovascular patients

Investigating the effect of Pentoxifylline for the treatment of mild to moderate major depression in cardiovascular patients after PCI or CABG

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20090117001556N132

Enrollment

Registered

2020-08-26

Start date

2020-09-10

Completion date

Unknown

Last updated

2020-09-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Major Depressive Disorder. Major depressive disorder, single episode, severe without psychotic features

Interventions

Intervention 1: Intervention group: Pentoxifylline tablet (Farabi co.) 800mg per day for 6 weeks. Intervention 2: Control group: placebo tablet per day for 6 weeks.

Eligibility

Sex/Gender

All

Age

40 Years to 60 Years

Inclusion criteria

Inclusion criteria: Diagnosis of mild to moderate major depressive disorder, based on DSM-5 Score between 14 to 17, based on Hamilton depression scale Age between 40 to 60 years Having heart disease undergoing PCI or CABG

Exclusion criteria

Exclusion criteria: Drug use during 1 year prior to trial Presence of concomitant psychiatric disorders Pregnant or lactating women History of Electroconvulsive therapy, two months prior to the trial Psychosis Thyroid disorders The patient's own request to leave the study

Design outcomes

Primary

Measure	Time frame
Severity of depression. Timepoint: Baseline and weeks 2, 4, and 6. Method of measurement: By Hamilton depression scale.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactShahin Akhondzadeh

Tehran University of Medical Sciences

s.akhond@sina.tums.ac.ir+98 21 5541 2222

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 21, 2026